Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced that CEO and Executive Chairman Ehud Geller will present at the 2026 ThinkEquity Conference on Oct. 15, 2026, at 10 a.m. at the Mandarin Oriental Hotel in New York City. The presentation will provide an overview of the company’s GelrinC(R) technology, recent clinical developments, progress in its ongoing U.S. Food and Drug Administration (“FDA”) pivotal Phase III trial, and preparations for commercialization in Europe, where GelrinC has received CE Mark approval. Geller and Chief Financial Officer Ori Gon will also be available for one-on-one meetings with investors. For full details, visit https://ibn.fm/wicmT.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. The lead product, GelrinC(R), is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. GelrinC aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
The ThinkEquity Conference presentation matters because it offers investors a direct update on Regentis’ clinical and commercial trajectory. With the FDA pivotal Phase III trial underway and CE Mark approval already secured in Europe, the company is positioning itself at the forefront of cartilage repair. If successful, GelrinC could become the first off-the-shelf solution for knee cartilage regeneration in the U.S., potentially transforming treatment paradigms for a condition that currently lacks convenient options. The one-on-one meetings may also provide institutional investors with deeper insight into the company’s strategy and milestones.
This content has been disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid investor awareness and marketing engagement. The latest news and updates relating to RGNT are available in the company’s newsroom at https//ibn.fm/RGNT.
MissionIR, a specialized communications platform, assists IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently reach target markets, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness. MIR is where breaking news, insightful content and actionable information converge. For more information, please visit www.MissionIR.com. Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer.
